Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical Application of <em>Sleeping Beauty</em> and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood

1 Feb 2013

Abstract excerpt

The potency of clinical-grade T cells can be improved by combining gene therapy with immunotherapy to engineer a biologic product with the potential for superior (i) recognition of tumor-associated antigens (TAAs), (ii) persistence after infusion, (iii) potential for migration to tumor sites, and (iv) ability to recycle effector functions within the tumor microenvironment. Most approaches to genetic manipulation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Viral Infectious Diseases and Gene Expression in Insects
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23407473
DOI: 10.3791/50070

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical Application of <em>Sleeping Beauty</em> and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord BloodPMID 23407473Read ↗

A new approach to gene therapy using <i>Sleeping Beauty</i> to genetically modify clinical‐grade T cells to target <scp>CD</scp>19Semantic proximity Read ↗

Redirecting Specificity of T-Cell Populations For CD19 Using the <i>Sleeping Beauty</i> SystemSemantic proximity Read ↗

Sleeping Beauty System to Redirect T-cell Specificity for Human ApplicationsSemantic proximity Read ↗

Generation and GMP scale-up of human CAR-T cells using non-viral Sleeping Beauty transposons for B cell malignancesSemantic proximity Read ↗

Sleeping Beauty Transposon‐mediated Engineering of Human Primary T Cells for Therapy of CD19+ Lymphoid MalignanciesSemantic proximity Read ↗

Development of CAR-T Cell Therapy for B-ALL Using a Point-of-Care ApproachSemantic proximity Read ↗

Generation of Genetically Engineered Precursor T-Cells From Human Umbilical Cord Blood Using an Optimized Alpharetroviral Vector Platform.Semantic proximity Read ↗

The Past, Present, and Future of Non-Viral CAR T CellsSemantic proximity Read ↗

Automated, scaled, transposon-based production of CAR T cellsSemantic proximity Read ↗

Transposon-Based CAR T Cells in Acute Leukemias: Where Are We Going?Semantic proximity Read ↗

Non-Viral Engineering of CAR-NK and CAR-T cells using the <i>Tc Buster</i> Transposon System™Semantic proximity Read ↗

Sleeping Beauty Transposition of Chimeric Antigen Receptors Targeting Receptor Tyrosine Kinase-Like Orphan Receptor-1 (ROR1) into Diverse Memory T-Cell Populations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.